Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, observational long-term follow-up trial of kidney transplant patients treated with imlifidase or plasma exchange after an active/chronic active Antibody-Mediated Rejection episode

Next Previous
Trial Profile

A prospective, observational long-term follow-up trial of kidney transplant patients treated with imlifidase or plasma exchange after an active/chronic active Antibody-Mediated Rejection episode

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlifidase (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Hansa Biopharma AB

Most Recent Events

  • 17 Apr 2023 This trial has been completed in France (End Date: 30 Mar 2023), according to European Clinical Trials Database record.
  • 14 Apr 2023 This trial has been completed in France (End Date: 30 Mar 2023), according to European Clinical Trials Database record.
  • 04 Apr 2023 Status changed from recruiting to discontinued (This is an internal decision based on prioritisations and no safety issues have been raisedduring the trial).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top